The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma. The U.S.

Roberto Mina, MD, discusses the distinguishing factors of the MajesTEC-3 and MajesTEC-9 trials of teclistamab in multiple ...

Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat ...

The FDA granted fast track designation to IBI3003 for patients with relapsed/refractory multiple myeloma after receiving four-plus lines of therapy.

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma ...

Data shows iberdomide combination therapy delivers progression free survival and safety in relapsed and refractory multiple myeloma after treatment.

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...

The FDA granted fast track designation (FTD) to IBI3003, a first-in-class trispecific antibody, for the treatment of patients ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...

Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...

All-oral therapies provide an attractive treatment option for patients with relapsed/refractory multiple myeloma, given their administration, the convenience of outpatient dosing, and the decreased ...